Comparison 5. Polyclonal antibody versus interleukin‐2 receptor antagonist.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Mortality	3	100	Risk Ratio (M‐H, Random, 95% CI)	1.41 [0.54, 3.70]
1.1 Basiliximab	1	24	Risk Ratio (M‐H, Random, 95% CI)	0.39 [0.02, 8.69]
1.2 Daclizumab	2	76	Risk Ratio (M‐H, Random, 95% CI)	1.62 [0.58, 4.46]
2 Acute rejection	2		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
2.1 Daclizumab	2	76	Risk Ratio (M‐H, Random, 95% CI)	1.35 [0.94, 1.94]
3 Adverse events	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
3.1 Daclizumab	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
4 Infection	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
4.1 Basiliximab	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
5 Pneumonia	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
5.1 Daclizumab	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
6 CMV infection	2		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
6.1 Daclizumab	2	76	Risk Ratio (M‐H, Random, 95% CI)	0.69 [0.17, 2.88]
7 Bronchiolitis obliterans syndrome	2		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
7.1 Daclizumab	2	76	Risk Ratio (M‐H, Random, 95% CI)	1.70 [0.42, 6.79]
8 Post‐transplantation lymphoproliferative disease (PTLD)	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
8.1 Daclizumab	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
9 Cancer	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
9.1 Daclizumab	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]